In Article 1 of this series, we explored how retatrutide may represent a significant shift in obesity pharmacotherapy rather than simply another iteration of GLP-1 receptor agonism. Through its combined targeting of GLP-1, GIP, and glucagon receptors, retatrutide appears capable of producing weight-loss reductions approaching the outcomes historically associated with bariatric surgery (Knerr et al., 2022; Madsbad & Holst, 2025; Sanyal et al., 2024). These effects are likely mediated by multiple complementary pathways, including appetite suppression, altered hypothalamic signaling, increased thermogenesis, and enhanced metabolic regulation (González-García et al., 2019; Smith et al., 2022; Yu et al., 2024).
At the same time, these profound physiological changes introduce an entirely new set of coaching considerations that personal trainers may increasingly need to navigate moving forward. More specifically, retatrutide raises a question that extends far beyond body weight alone: What happens when physiology changes faster than behavior, movement competency, recovery systems, and psychological adaptation can realistically keep pace?
That question may ultimately become one of the defining coaching challenges of the next decade.
Because while retatrutide may dramatically alter body weight and metabolic health markers, it does not automatically improve movement quality, muscular strength, physical resilience, or long-term lifestyle behaviors. Those remain deeply behavioral, physical, and human processes that still require structure, progression, and coaching (Locatelli et al., 2024; Vikberg et al., 2019).
Rapid Weight Loss Does Not Automatically Produce High Performance
One of the more interesting tensions emerging throughout the retatrutide literature is the growing disconnect between external appearance and internal physical capacity. Clients may experience rapid reductions in body weight and body fat while simultaneously struggling with muscular weakness, low energy availability, diminished recovery capacity, or poor tolerance to resistance training (Locatelli et al., 2024; Madsbad & Holst, 2025).
This distinction is critically important because scale weight alone tells us very little about how well an individual can actually function.
For example, an individual may lose a substantial amount of body weight over a relatively short period of time yet still struggle climbing stairs without fatigue, carrying heavy luggage through an airport, or generating force quickly enough to recover from a missed step on uneven ground. Externally, that individual may appear healthier. Functionally, however, they may still lack the muscular strength, work capacity, and physical confidence necessary to move effectively through daily life.
This becomes especially relevant given the growing concern surrounding lean mass reductions during incretin-based pharmacotherapy. Current evidence suggests that more than one-quarter of total weight lost during these interventions may originate from fat-free mass, including skeletal muscle tissue (Locatelli et al., 2024). In some studies, reductions in lean mass approached nearly 10% of total body weight over 48–72 weeks.
From a muscle-centric perspective, this creates an important paradox. A client may become substantially lighter while simultaneously becoming less physically capable. Over time, this may increase vulnerability to age-related sarcopenia, reductions in functional independence, and diminished movement confidence, particularly among aging populations already vulnerable to muscle loss (Cereda et al., 2022; Vikberg et al., 2019).
That distinction fundamentally changes the coaching conversation.
The Growing “Behavior Lag”
Perhaps one of the most overlooked implications of aggressive obesity pharmacotherapy is what might best be described as a growing “behavior lag.” In many cases, physiology may now change faster than behavior can adapt.
Historically, body composition changes tended to occur gradually enough that individuals were forced to develop at least some degree of behavioral adaptation alongside physical change. Weight loss often requires sustained changes in dietary habits, movement behaviors, exercise adherence, sleep routines, and stress management strategies over extended periods.
Retatrutide may alter that dynamic considerably.
A client may now lose 40, 50, or even 60 pounds before they have fully developed sustainable resistance training habits, consistent recovery routines, or identity-level behavioral change. Externally, the transformation may occur rapidly. Internally, however, many of the systems supporting long-term sustainability may still lag behind.
This creates a potentially important mismatch.
In many cases, clients may appear dramatically different while still lacking movement competency, physical resilience, or confidence under load. Put differently, the physiology changes rapidly while the behavioral infrastructure supporting that physiology remains relatively underdeveloped.
That is not simply a programming challenge. It is a systems challenge.
And increasingly, it may become one of the primary areas in which skilled personal trainers provide value. In many ways, this reinforces the growing importance of trainers who understand not only fat-loss physiology but also long-term adaptation, recovery management, and muscle preservation strategies during periods of rapid metabolic change (Locatelli et al., 2024; Phillips, 2014).
Appetite Suppression Creates Recovery Challenges
Another major consideration in the retatrutide era involves recovery management. Because these medications substantially suppress appetite, many clients may unintentionally underconsume calories, protein, and micronutrients necessary to support resistance-training adaptation and muscle protein synthesis (Phillips, 2014).
The literature consistently recommends elevated protein intake during incretin therapy, generally ranging from 1.6–2.2 g/kg/day (Phillips, 2014). However, achieving these targets may become increasingly difficult in individuals experiencing profound satiety and diminished hunger signaling secondary to altered hypothalamic appetite regulation (Smith et al., 2022).
This creates a coaching scenario that differs substantially from traditional weight-loss interventions. Historically, many trainers worked primarily with clients attempting to improve dietary restraint. Increasingly, however, trainers may encounter clients who struggle to consume enough high-quality nutrition to adequately support recovery, muscle preservation, and training progression.
Over time, this may contribute to excessive fatigue, reduced training quality, impaired recovery capacity, or progressive strength loss despite ongoing reductions in body weight.
In practical terms, the client may become smaller without necessarily becoming stronger, healthier, or more physically resilient.
As a result, concepts such as protein distribution, leucine-rich nutrition strategies, nutrient timing, and recovery management may increasingly become foundational coaching competencies rather than advanced performance concepts. This becomes especially relevant given emerging evidence supporting leucine-enriched whey protein interventions as potentially valuable strategies for attenuating sarcopenia-related muscle loss during periods of physiological stress and reduced intake (Cereda et al., 2022).
Why Resistance Training Becomes Even More Important
One of the more counterintuitive implications of the retatrutide era is that resistance training may become increasingly important as pharmacotherapy becomes more effective.
At first glance, some individuals may assume that dramatic medication-induced weight loss reduces the need for structured exercise. However, the literature strongly suggests the opposite may be true. Resistance training remains one of the most evidence-supported interventions for preserving lean mass, improving strength, and supporting long-term functional capacity during periods of rapid weight reduction (Locatelli et al., 2024; Vikberg et al., 2019).
More importantly, resistance training provides adaptations that pharmacotherapy alone cannot fully replicate.
While medications may significantly reduce body weight, they cannot independently improve neuromuscular coordination, movement competency, force production, power development, connective tissue adaptation, or physical confidence under load. These remain highly trainable qualities that require progressive exposure to resistance exercise.
For example, pharmacotherapy may help reduce the mechanical burden associated with obesity, but it cannot teach an individual how to properly hinge, stabilize under load, absorb force efficiently, or generate power quickly enough to prevent a fall. Those remain profoundly trainable human adaptations that require repeated exposure to progressively overloaded movement patterns (Locatelli et al., 2024; Vikberg et al., 2019).
These capacities may become even more valuable as obesity pharmacotherapy becomes increasingly widespread across aging populations already vulnerable to sarcopenia and functional decline (Cereda et al., 2022; Vikberg et al., 2019).
The Shift From Weight-Loss Coaching to Capacity Coaching
One of the broader implications of retatrutide is that it may fundamentally shift what clients need from fitness professionals moving forward.
Historically, many trainers differentiated themselves primarily through their ability to help clients lose body weight. However, as pharmacologic interventions become increasingly capable of inducing dramatic weight reduction independently, the trainer’s role may increasingly evolve toward helping clients preserve and rebuild physical capacity.
This includes preserving skeletal muscle, improving movement quality, supporting metabolic resilience, maintaining strength, and helping clients sustain long-term behavioral consistency as their physiology changes rapidly (Cereda et al., 2022; Locatelli et al., 2024; Phillips, 2014).
In this regard, the future trainer may increasingly resemble a muscle-preservation specialist, movement professional, recovery strategist, and performance-oriented behavior-change coach simultaneously.
That evolution creates substantial opportunity.
Because while medications may continue improving at altering physiology through increasingly sophisticated hormonal and metabolic pathways (González-García et al., 2019; Yu et al., 2024), they cannot independently create movement literacy, training consistency, physical resilience, or sustainable long-term lifestyle behaviors. Those remain highly coach-dependent outcomes.
Why Functional Metrics Matter More Than Ever
As obesity pharmacotherapy evolves, trainers may also need to reconsider how progress is measured.
Scale weight alone is becoming increasingly insufficient.
The literature repeatedly highlights the need for more robust assessment of grip strength, gait speed, muscle power, physical function, and long-term sarcopenia risk during incretin therapy (Locatelli et al., 2024; Vikberg et al., 2019).
This creates an important opportunity for personal trainers to expand beyond purely aesthetic tracking metrics. Progress may increasingly be evaluated through improvements in strength, movement quality, balance, work capacity, recovery, and overall physical confidence rather than body weight alone.
In many cases, these markers may ultimately prove far more meaningful than reductions in scale weight.
Retatrutide may represent one of the most significant shifts in obesity pharmacotherapy to date. Its unprecedented ability to induce rapid weight reduction introduces tremendous potential benefits for metabolic health, cardiovascular risk reduction, and quality of life (Madsbad & Holst, 2025; Sanyal et al., 2024).
At the same time, these rapid physiological changes introduce new coaching complexities surrounding skeletal muscle preservation, recovery capacity, functional performance, and long-term behavioral sustainability (Cereda et al., 2022; Locatelli et al., 2024; Phillips, 2014).
For personal trainers, this changing landscape represents more than a challenge. It represents an opportunity to evolve beyond traditional fat-loss coaching and toward a more comprehensive model centered on strength, movement quality, resilience, and long-term human performance.
Ultimately, the professionals who thrive in the retatrutide era may not simply be those who help clients become lighter. They may be the coaches who ensure clients remain strong, physically capable, and functionally resilient while doing so.
References
Cereda, E., Pisati, R., Rondanelli, M., & Caccialanza, R. (2022). Whey protein, leucine- and vitamin D-enriched oral nutritional supplementation for the treatment of sarcopenia. Nutrients, 14(7), 1524. https://doi.org/10.3390/nu14071524
González-García, I., Milbank, E., Diéguez, C., López, M., & Contreras, C. (2019). Glucagon receptor signaling and energy homeostasis. Molecular and Cellular Endocrinology, 418, 28–37.
Knerr, P. J., et al. (2022). Next-generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice. Molecular Metabolism, 63, 101533. https://doi.org/10.1016/j.molmet.2022.101533
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L., Fegan, P., Yeap, B. B., & Green, D. J. (2024). Incretin-based weight loss pharmacotherapy: Can resistance exercise optimize changes in body composition? Diabetes Care, 47(10), 1734–1742. https://doi.org/10.2337/dci23-0100
Madsbad, S., & Holst, J. J. (2025). The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: A look at phase 2 and 3 pipelines. Expert Opinion on Investigational Drugs, 34(3), 197–215. https://doi.org/10.1080/13543784.2025.2472408
Phillips, S. M. (2014). A brief review of critical processes in exercise-induced muscular hypertrophy. Sports Medicine, 44(Suppl. 1), S71–S77.
Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M., Harris,C., Schloot, N. C., Du, Y., Mather, K., Haupt, A., & Hartman, M. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial. Nature Medicine, 30(8), 2214–2223. https://doi.org/10.1038/s41591-024-03018-2
Smith, C. A., Patterson-Cross, R. B., Woodward, O. R. M., Lewis, J., Chiarugi, D., Merkle, F., Gribble, F. M., Reimann, F., & Adriaenssens, A. E. (2022). A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus. Appetite, 177, 106022. https://doi.org/10.1016/j.appet.2022.106022
Vikberg, S., Sörlén, N., Brännström, M., Bucht, G., Stenlund, H., & Rosendahl, E. (2019). Effects of resistance training on functional strength and muscle mass in older adults with sarcopenia. Journal of the American Medical Directors Association, 20(1), 28–34.
Yu, Y., et al. (2024). GIP receptor agonism enhances adipocyte thermogenesis and metabolic regulation. Cell Metabolism, 36(2), 214–228.
